John T. Farrar
John T. Farrar, M.D., Ph.D., has been involved in clinical research for more than 25 years, with a major focus on the study of the efficacy of pain therapeutics and on novel methodology in the design and execution of clinical trials. As a neurologist and a pharmaco-epidemiologist, he has been involved in numerous studies including randomized trials (RCTs), cohort studies, and methodologic studies of pain and associated symptoms such as fatigue, depression, and quality of life in clinical research and practice; these have been conducted with funding he has received from the National Institutes of Health, the U.S. Food and Drug Administration (FDA), private foundations, and industry sources. Currently, he is the Principal Investigator of an FDA funded contract to study the use of opioids in treating pain, the Principal Investigator of the Center of Excellence for Pain Education, he directs the evaluation component of Penn's current Clinical and Translational Science Award (CTSA), and he is a collaborator with the data coordinating center for the U54 multicenter Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) study. Nationally he has served on advisory boards for the FDA, on the National Academy of Science (NAS) committee on Missing Data in Clinical Trials, and on the Institute of Medicine’s (IOM) committee on Relieving Pain in America. He continues to serve roles as an ad hoc reviewer for NIH and the FDA, and as associate editor for the journal Pharmacoepidemiology and Drug Safety (PDS). His current research is focused on the evaluation of new methodologies for understanding how patients report their pain, studies in a large population of patients with pelvic pain, and functional brain imaging in people with pain. At the University of Pennsylvania Perelman School of Medicine, he has co-directed the Biostatistical Analysis Center and the Master of Science in Clinical Epidemiology (MSCE) program for more than ten years. He directs the Introduction to Epidemiology course for medical students. In addition, he continues to see patients, predominately in a palliative care setting.
Carmen R. Green
Carmen Green, M.D., a tenured professor of anesthesiology, with joint appointments in the Medical School's Department of Obstetrics and Gynecology and the Department of Health Management and Policy in the School of Public Health at the University of Michigan. She is co-director for the Community Liaison Core and director of the Healthier Black Elders Center for the Michigan Center for Urban African American Aging Research at the U-M Institute for Social Research. Her research focuses on pain management outcomes, physician decision-making, and access to care - and has documented disparities due to age, race, gender, and class across the lifespan. She has also found community-based structural barriers to health and pain care, including clear disparities in access to pain medication for blacks, women and low-income individuals with chronic pain. Her leadership in developing and diversifying the health professional pipeline includes service on faculty and advisory boards for programs designed to achieve a critical mass of minorities and women in biomedical science. She has been selected for several fellowships focusing on aging, health care and health policy, including the Robert Wood Johnson Health Policy Fellowship at the Institute of Medicine of the National Academies -- where she worked as a health policy analyst on the U.S. Senate's Health Education, Labor, and Pensions Committee and the Children and Families Subcommittee. She is an elected fellow of the New York Academy of Medicine, the Gerontological Society of America, and the Association of University Anesthesiologists. Her work has informed the policy agenda and she has provided expert testimony to state and federal entities.
Dr. Friedhelm Sandbrink, M.D., is the National Program Director for Pain Management, within the Office of Specialty Care Services in VHA. Dr. Sandbrink completed his residency in Neurology at Georgetown University in Washington DC, and fellowship in Clinical Neurophysiology at the NIH. He is board-certified in Neurology, Clinical Neurophysiology and Pain Medicine. He is Clinical Associate Professor in Neurology at the Uniformed Services University in Bethesda, MD and Assistant Clinical Professor of Neurology at George Washington University in Washington DC. Dr. Sandbrink joined the Department of Veterans Affairs in 2001 and since then has been leading the comprehensive interdisciplinary Pain Management Program within the Neurology Department at the Washington VA Medical Center. He was appointed Deputy National Program Director in VHA in 2014. After serving in Acting capacity (since Oct. 2016), he became the National Program Director for Pain Management in September 2018. He participates in many VHA and national Pain Management initiatives including the Pain Management Best Practices Federal Inter-Agency Task Force (by the Department of Health and Human Services) and the National Pain Strategy Implementation Workgroups. He also participated in the writing of the VA/DoD Clinical Practice Guidelines for Opioid Therapy and for Low Back Pain.
Vinod P. Shah, Ph.D., joined NDA Partners as an Expert Consultant in 2016. He has thirty years of experience at the FDA, working in different Divisions, until he retired as a Senior Research Scientist in the Office of Pharmaceutical Sciences in 2005. During his career at FDA, he developed several regulatory guidances for Industry in areas such as dissolution, SUPAC, bioanalysis, bioequivalence, biopharmaceutics, and topical drugs. In addition to his career at FDA, Dr. Shah worked at Sarabhai Chemicals, Baroda, India. He served as Scientific Secretary of the International Pharmaceutical Federation (FIP), as Adjunct faculty at JSS University, India, and Adjunct Professor at College of Pharmacy, University of Kentucky. Dr. Shah is a former Biopharmaceutics Expert Committee member of USP. He was Co-Chair of USP’s Advisory Panel on Dosage Form Performance – Topical/Dermal, and Distinguished Pharmaceutical Scientist/Consultant at USP in Biopharmaceutics. He is a member of the Steering Committee of Non-Biological Complex Drugs (hosted at Lygature, The Netherlands), and Founder and Chairman of the Society of Pharmaceutical Dissolution Science (SPDS) International. In addition, Dr. Shah was a Board Member of the Product Quality Research Institute (PQRI) from 2013-2017 and holds two Honorary Doctorates from Semmelweis University, Hungary and the University of Medicine and Pharmacy “Carol Davila” Bucharest, Romania.
Joyce S. Tsuji
Joyce S. Tsuji, Ph.D., DABT, is a board-certified toxicologist and a Fellow of the Academy of Toxicological Sciences. She specializes in assessing exposure and risks associated with chemicals, and in communication of scientific issues. Dr. Tsuji has worked on projects in the United States and internationally for industry, trade associations, U.S. EPA and state agencies, the U.S. Department of Justice, the Australian EPA, municipalities, and private citizens. Her experience includes toxicology and risk assessment related to a wide variety of chemicals in the environment, work place, food, consumer and personal care products, pharmaceuticals, and medical devices. She has designed and directed dietary and environmental exposure studies and community programs involving health education and biomonitoring for populations potentially exposed to chemicals in the environment, including soil, water, and food-chain exposures. She has served on expert panels on toxicology and health risks issues for the National Academy of Sciences/National Research Council (including their Board on Environmental Studies and Toxicology), Institute of Medicine, and federal and state agencies. Dr. Tsuji earned her BS in Biological Sciences from Stanford University and PhD focused in Environmental Physiology from the Department of Zoology, University of Washington.
Carol S. Wood
Carol S. Wood, Ph.D., is a distinguished staff scientist in the Environmental Science Division of Oak Ridge National Laboratory. She has over 20 years of experience as a toxicologist, with extensive work performing risk assessments of inhalation/pulmonary and oral toxicity from exposure to a variety of chemicals. Her past work has included developing acute exposure guideline levels and provisional advisory levels, in which health-based exposure levels are developed for priority toxic chemicals. These projects often used toxicokinetic data and physiologically based pharmacokinetic models for extrapolating animal toxicology data to humans. Dr. Wood is a past-president of the American Board of Toxicology. She is certified in general toxicology by the American Board of Toxicology. She served on the National Academies Committee on the Review of Clinical Guidance for the Care of Health Conditions Identified by the Camp Lejeune Legislation, and the Committee on Spacecraft Exposure Guidelines, and currently serves on the Committee on Gulf War and Health, Volume 11 (Generational Health Effects of Serving in the Gulf War); she current serves on the Committee on Toxicology. Dr. Wood received her MS in toxicology from Mississippi State University and her PhD in toxicology from Oregon State University.
Leigh Jackson - (Staff Officer)
Leigh Miles Jackson, PhD, (Study Director) is a Senior Program Officer on the Board on Health Sciences Policy (HSP) and serves as the study director for two FDA-sponsored consensus studies related to compounded drug product —one that focuses on the utility of treating patients with compounded bioidentical hormone therapy, and another that focuses on the safety and effectiveness of compounded topical pain creams. Prior to her work on HSP, Leigh served on the Board on Higher Education and Workforce where she directed the consensus study, Minority Serving Institutions: America's Underutilized Resource for Strengthening the STEM Workforce. Prior to this, Leigh worked in the Health and Medicine Division and directed the reports, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research and Advancing the Power of Economic Evidence to Inform Investments in Children, Youth, and Families. Prior to joining the National Academies, she was a developmental psychopathology and neurogenomics research fellow at Vanderbilt University, where she investigated the role of chronic sleep disturbance and specific epigenetic modifications on the health outcomes of adolescents. Leigh has a bachelor’s degree in chemistry from Wake Forest University and a Ph.D. in molecular and systems pharmacology from Emory University.